Elixir’s rights to this patent were made possible through an exclusive license. Sirtuins are a class of enzymes believed to play a significant role in diseases of aging, including type 2 diabetes and obesity. This new patent adds to the company’s broad portfolio of issued patents and patent applications related to the development of sirtuin-based therapeutics.
William Heiden, Elixir’s president and CEO, said: “Our portfolio includes not only broad issued and filed patents such as this new patent, but also positions having specific composition claims covering pharmaceutical compounds which are modulators (both activators and inhibitors) of key sirtuin enzymes and utility in major disease categories.”